Literature DB >> 25295224

Texaphyrins and water-soluble zinc(II) ionophores: development, mechanism of anticancer activity, and synergistic effects.

Christian Preihs1, Darren J Magda2, Jonathan L Sessler3.   

Abstract

Texaphyrins, first prepared by Sessler and coworkers in the 1980s, represent early examples of expanded porphyrins. This class of pentaaza, oligopyrrolic macrocycles demonstrates excellent tumor localization and metal-chelating properties. In biological milieus, texaphyrins act as redox mediators and are able to produce reactive oxygen species. Furthermore, texaphyrins have been shown to upregulate zinc in vivo, an important feature that inspired us to develop new zinc ionophores that might allow the same function to be elicited but via a simpler chemical means. In this review, the basic properties of texaphyrins and the zinc ionophores they helped spawn will be discussed in the cadre of developing an understanding that could lead to the preparation of new, redox-active anticancer agents.

Entities:  

Keywords:  MRI contrast agents; expanded porphyrins; porphyrins; radiation sensitizers; reactive oxygen species; zinc ionophores

Year:  2013        PMID: 25295224      PMCID: PMC4185204          DOI: 10.1515/irm-2013-0001

Source DB:  PubMed          Journal:  Bioinorg React Mech        ISSN: 2191-2483


  56 in total

Review 1.  Application of metabolomics to prostate cancer.

Authors:  Bruce J Trock
Journal:  Urol Oncol       Date:  2011 Sep-Oct       Impact factor: 3.498

2.  Differential zinc accumulation and expression of human zinc transporter 1 (hZIP1) in prostate glands.

Authors:  Leslie A Johnson; Mazhar A Kanak; Andre' Kajdacsy-Balla; Joseph P Pestaner; Omar Bagasra
Journal:  Methods       Date:  2010-08-10       Impact factor: 3.608

Review 3.  Introduction to metallothionein.

Authors:  B L Vallee
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

Review 4.  Zinc is decreased in prostate cancer: an established relationship of prostate cancer!

Authors:  Leslie C Costello; Renty B Franklin
Journal:  J Biol Inorg Chem       Date:  2010-12-08       Impact factor: 3.358

5.  Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial.

Authors:  Derek R McHaffie; Pierre Chabot; Anne Dagnault; John H Suh; Marie-Andrée Fortin; Eric Chang; Robert Timmerman; Luis Souhami; John Grecula; Abdenour Nabid; Chris Schultz; Maria Werner-Wasik; Laurie E Gaspar; David Brachman; Tarak Mody; Minesh P Mehta
Journal:  J Neurooncol       Date:  2011-04-27       Impact factor: 4.130

6.  Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging.

Authors:  S W Young; M K Sidhu; F Qing; H H Muller; M Neuder; G Zanassi; T D Mody; G Hemmi; W Dow; J D Mutch
Journal:  Invest Radiol       Date:  1994-03       Impact factor: 6.016

7.  Zinc pyridinethione: serum metabolites of zinc pyridinethione in rabbits, rats, monkeys, and dogs after oral dosing.

Authors:  W B Gibson; A R Jeffcoat; T S Turan; R H Wendt; P F Hughes; M E Twine
Journal:  Toxicol Appl Pharmacol       Date:  1982-02       Impact factor: 4.219

8.  Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species.

Authors:  Darren Magda; Nikolay Gerasimchuk; Philip Lecane; Richard A Miller; John E Biaglow; Jonathan L Sessler
Journal:  Chem Commun (Camb)       Date:  2002-11-21       Impact factor: 6.222

9.  Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Authors:  Minesh P Mehta; Patrick Rodrigus; C H J Terhaard; Aroor Rao; John Suh; Wilson Roa; Luis Souhami; Andrea Bezjak; Mark Leibenhaut; Ritsuko Komaki; Christopher Schultz; Robert Timmerman; Walter Curran; Jennifer Smith; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

10.  hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer.

Authors:  Renty B Franklin; Pei Feng; B Milon; Mohamed M Desouki; Keshav K Singh; André Kajdacsy-Balla; Omar Bagasra; Leslie C Costello
Journal:  Mol Cancer       Date:  2005-09-09       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.